InMed Pharmaceuticals Inc. Common Shares
INMInMed Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies derived from its core expertise in cannabinoid science. The company explores the potential medical applications of cannabinoids to treat various health conditions and aims to leverage its proprietary drug development platform to bring novel treatments to market.
Company News
Law firm Brodsky & Smith is investigating potential breaches of fiduciary duty by InMed Pharmaceuticals' Board of Directors regarding the company's sale to Mentari Therapeutics. The investigation focuses on whether the Board conducted a fair process and whether shareholders are receiving fair value, with InMed shareholders expected to own approxi...
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insid...
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider ...
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. BlackBerry reported quarterly earnings of 1 cent per share which exceeded the Street's estimate of losses of 3 cents per share, according to Benzinga Pro. The company also said it sees fourth-quarter revenue of $150 million ...
Global X’s investment chief, Jon Maier, reflects on the investment landscape for 2024, which is shaping up to be particularly interesting, thanks to AI-related stocks, cloud computing, cybersecurity, emerging markets, and small caps for potential growth. What Happened: Maier, who is associated with the  $48 billion award-winning AI exchange-tr...
